Development of Peptide-Based Lineage-Specific Serology for Chronic Chagas Disease: Geographical and Clinical Distribution of Epitope Recognition

22 May 2014
Tapan Bhattacharyya, Andrew K. Falconar,Alejandro O. Luquetti,Jaime A. Costales,Mario J. Grijalva,Michael D. Lewis,Louisa A. Messenger,Trang T. Tran,Juan-David Ramirez,Felipe Guhl,Hernan J. Carrasco,Patricio Diosque,Lineth Garcia,Sergey V. Litvinov,Michael A. Miles

Chagas disease, caused by infection with the protozoan Trypanosoma cruzi, remains a serious public health issue in Latin America. Genetically diverse, the species is sub-divided into six lineages, known as TcI–TcVI, which have disparate geographical and ecological distributions. TcII, TcV, and TcVI are associated with severe human disease in the Southern Cone countries, whereas TcI is associated with cardiomyopathy north of the Amazon. T. cruzi persists as a chronic infection, with cardiac and/or gastrointestinal symptoms developing years or decades after initial infection. Identifying an individual's history of T. cruzi lineage infection directly by genotyping of the parasite is complicated by the low parasitaemia and sequestration in the host tissues.